Plain-English translation of NCT07085676 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase 1 trial is testing , a personalized cell treatment designed to help people with severe autoimmune diseases like lupus, scleroderma, myositis, and multiple sclerosis that have not responded to standard treatments. Researchers will collect your immune cells, modify them in a laboratory to target the B cells driving your disease, and then give them back to you as a single infusion. The study will carefully monitor your safety and how well the treatment works over the next 4 years.
Most people with severe autoimmune diseases can control their condition with existing medications, but some patients don't respond to these standard treatments or can't tolerate them. This medication represents a completely new approach—using your own modified immune cells to fight the disease—and this trial is testing whether it's safe and effective for these hard-to-treat patients.
You likely qualify if…
You likely don't qualify if…
If enrolled, you'll first have a procedure called leukapheresis to collect your immune cells (similar to donating blood). Your cells will then be sent to a laboratory to be modified over several weeks. Once ready, you'll receive medication to prepare your body, then receive a single infusion of your modified cells and stay in the hospital for several days for monitoring. After that, you'll return for regular follow-up visits and blood tests at set intervals for up to 4 years to track your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Israel